View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsCOVA Acquisition 過去の業績過去 基準チェック /16主要情報8.96%収益成長率n/aEPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Sep 2022最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Dec 21ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction.ECARX Holdings Inc. entered into a letter of intent to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on September 21, 2021. ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company. At the closing, current ECARX shareholders will roll their existing equity holdings into the post-business combination company. Upon completion of the transaction, the combined company expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The shareholders of COVA will hold a meeting on December 14, 2022 to approve the transaction. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. As of November 18, 2022, the registration statement has been declared effective by the U.S. Securities and Exchange Commission with respect to the transaction. On December 14, 2022,COVA Acquisition shareholders approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel. COVA has hired D.F. King & Co., Inc. to assist in the proxy solicitation process. COVA will pay to D.F. King & Co., Inc. a fee of $25,000, plus disbursements. Mark Zimkind of Continental Stock Transfer & Trust Company served as transfer agent to COVA. PriceWaterhouseCoopers Advisory LLC acted as the financial advisor and PricewaterhouseCoopers LLP and Roland Berger LLC acted as the due diligence advisors to COVA. ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on December 20, 2022.お知らせ • May 27ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion.ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company, Upon completion of the transaction expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel.お知らせ • Apr 09Cova Acquisition Talks with Tiket.Com Reportedly EndedTiket.com has ended talks to come public through a merger with special purpose acquisition company COVA Acquisition Corp., according to Bloomberg's Gillian Tan, Manuel Baigorri, Fathiya Dahrul and Elffie Chew, citing people familiar with the matter. Tiket is now considering a merger with e-commerce platform Blibli, formerly known as PT Global Digital Niaga, instead, the report said.お知らせ • Jun 03COVA Acquisition Corp Receives Expected Notice from Nasdaq Regarding Delayed Form 10-QOn May 28, 2021, COVA Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate impact on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously reported in the Form 12b-25 filed with the SEC on May 17, 2021, the Company was unable to file the First Quarter 2021 Form 10-Q by the prescribed due date of May 17, 2021 without unreasonable effort and expense. The Company was unable to file the First Quarter 2021 Form 10-Q by the extension date of May 24, 2021 but subsequently filed the First Quarter 2021 Form 10-Q with the SEC on June 1, 2021. As a result of such filing, the Company expects to regain compliance with the Nasdaq Listing Rule.お知らせ • May 18COVA Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, COVA Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.収支内訳COVA Acquisition の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:COVA 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 22096030 Jun 220145031 Mar 220222031 Dec 2101220質の高い収益: COVAは 高品質の収益 を持っています。利益率の向上: COVAの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: COVAは株式公開されてから 3 年未満しか経っていないため、過去 5 年間の前年比収益成長率がプラスであったかどうかを判断できません。成長の加速: COVAは株式公開されてから 3 年未満であるため、過去 1 年間の収益成長を 5 年間の平均と比較することはできません。収益対業界: COVAの過去 1 年間の収益成長率 ( 9% ) Capital Markets業界39.3%を上回りませんでした。株主資本利益率高いROE: COVAの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/21 22:48終値2022/12/20 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋COVA Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 21ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction.ECARX Holdings Inc. entered into a letter of intent to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on September 21, 2021. ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company. At the closing, current ECARX shareholders will roll their existing equity holdings into the post-business combination company. Upon completion of the transaction, the combined company expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The shareholders of COVA will hold a meeting on December 14, 2022 to approve the transaction. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. As of November 18, 2022, the registration statement has been declared effective by the U.S. Securities and Exchange Commission with respect to the transaction. On December 14, 2022,COVA Acquisition shareholders approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel. COVA has hired D.F. King & Co., Inc. to assist in the proxy solicitation process. COVA will pay to D.F. King & Co., Inc. a fee of $25,000, plus disbursements. Mark Zimkind of Continental Stock Transfer & Trust Company served as transfer agent to COVA. PriceWaterhouseCoopers Advisory LLC acted as the financial advisor and PricewaterhouseCoopers LLP and Roland Berger LLC acted as the due diligence advisors to COVA. ECARX Holdings, Inc. completed the acquisition of COVA Acquisition Corp. (NasdaqCM:COVA) from COVA Acquisition Sponsor LLC and others in a reverse merger transaction on December 20, 2022.
お知らせ • May 27ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion.ECARX Holdings Inc. entered into an agreement to acquire COVA Acquisition Corp. (NasdaqCM:COVA) in a reverse merger transaction for $3.4 billion on May 26, 2022. The transaction values ECARX at $3.82 billion pro forma equity value, or pre-money equity value of $3.4 billion. After the closing of the merger, ECARX’s existing shareholders are expected to own approximately 89% of the pro forma combined company, Upon completion of the transaction expects to be listed on Nasdaq under ticker symbol "ECX". The transaction will require the approval of the shareholders of both ECARX and COVA and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The Boards of Directors of ECARX and COVA have unanimously approved the transaction. The closing of the transaction is expected to occur in the fourth quarter of 2022. Proceeds from the transaction will be used to accelerate technology development and the roll-out of new products, support strategic acquisitions or investments, as well as create further pathways for global growth through its international operations office in London and a product development center in Gothenburg, Sweden. UBS AG Hong Kong Branch and Morgan Stanley Asia Limited acted as joint financial advisors to ECARX. Skadden, Arps, Slate, Meagher & Flom acted as international legal counsel to ECARX. Cantor Fitzgerald & Co. acted as capital markets advisor to COVA Acquisition Corp., and Orrick, Herrington & Sutcliffe LLP acted as its legal counsel.
お知らせ • Apr 09Cova Acquisition Talks with Tiket.Com Reportedly EndedTiket.com has ended talks to come public through a merger with special purpose acquisition company COVA Acquisition Corp., according to Bloomberg's Gillian Tan, Manuel Baigorri, Fathiya Dahrul and Elffie Chew, citing people familiar with the matter. Tiket is now considering a merger with e-commerce platform Blibli, formerly known as PT Global Digital Niaga, instead, the report said.
お知らせ • Jun 03COVA Acquisition Corp Receives Expected Notice from Nasdaq Regarding Delayed Form 10-QOn May 28, 2021, COVA Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the “Q1 2021 Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC. The Notice has no immediate impact on the listing or trading of the Company’s securities on the Nasdaq Capital Market. As previously reported in the Form 12b-25 filed with the SEC on May 17, 2021, the Company was unable to file the First Quarter 2021 Form 10-Q by the prescribed due date of May 17, 2021 without unreasonable effort and expense. The Company was unable to file the First Quarter 2021 Form 10-Q by the extension date of May 24, 2021 but subsequently filed the First Quarter 2021 Form 10-Q with the SEC on June 1, 2021. As a result of such filing, the Company expects to regain compliance with the Nasdaq Listing Rule.
お知らせ • May 18COVA Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, COVA Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.